Cracking the cost-care code: Supporting complex conditions without compromise
Plan sponsors are no stranger to balancing rising pharmacy costs and helping members with complex conditions get the care they need. Unfortunately, this juggling act is only going to get harder. Recent reports predict that employer coverage costs could rise nearly 10% in 2026.1 And specialty medications now make up over half of drug spend, yet only account for 2% of prescriptions.2
At CVS Caremark®, cost management and compassionate care go hand in hand. We partner with plan sponsors on sustainable solutions, so we can focus on supporting members on their journey to better health.
Humanizing high-cost care decisions
Members with rare, chronic or complex conditions like cancer or multiple sclerosis often need life-saving, but expensive, medications. These members cost four times more than the average.3 Supporting them is not only the right thing to do — it’s solid business practice. Covering less care can actually lead to higher long-term costs, from emergency room visits to absenteeism and disability.
Bringing a holistic approach to health care
CVS Caremark’s customized, clinical-first strategies strike the right balance between helping clients meet cost targets and providing members with the quality health care they need. Our solutions center on three main areas — formulary, individualized client support and technology.
1. Predictive analytics and precision formulary
Our Clinical Pipeline Services team continuously tracks drugs in development like GLP-1s, gene therapies and biosimilars. We share these insights with clients, so they’re up to date on new treatments and their impact on plans and costs.
We’re also the industry leader in adopting biosimilars and generics to control drug spend without compromising care. We were the first pharmacy benefit manager (PBM) to remove Humira® from our formulary and replace it with a biosimilar for a $0 copay, saving clients and members money.
$1.5B gross savings through our biosimilar strategy4
2. Clinical advisor support
Our clinical advisors regularly review data from prescription and medical claims, lab results, and demographic and biometric information. They find any gaps in care and recommend customized programs to keep members with complex conditions motivated, adherent and on track. These may include programs like Accordant®, CVS Weight Management™ and Transform Diabetes Care®.
These solutions give members personalized interventions like one-on-one nurse support, nutrition planning, medication reminders and drug counseling. Clients see the benefits through improved outcomes and lower medical costs.
8.8% reduction in all-cause hospitalizations for Accordant Rare members5
42% savings when GLP-1s paired with weight management support6
3. Member-focused technology and care
We’re integrated with electronic health records so providers have immediate access to drug costs and lower priced alternatives. We use technology to automatically route prior authorization (PA) requests, reducing the average handle time per case.
Our smart digital tools help members track their medication status, refills and PAs. We also proactively contact members who may need reminders or extra help for their condition through their preferred channels. Together, these experiences promote simplicity, savings and satisfaction for members and clients.
>90% of PAs are approved within one day7
Outcomes that matter
The results of our approach are clear: smarter strategies, tailored interventions and technology lead to improved health outcomes, satisfaction and savings.
- $24.3M annual medical cost savings with Transform Diabetes Care8
- ~35% decrease in diabetes-specific drug spend9
- $3,723 savings per member per year with Accordant Rare5
- 93% overall member satisfaction, 96% client satisfaction10, 11
Compassion and cost control can coexist
The push and pull between cost and quality care is real. With the right PBM, clients can be both compassionate and fiscally responsible.
-
-
2 CVS Health Analytics, 2024. Data from Commercial Book of Business, 2023. All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. P1014800723
-
3 CVS Health Analytics, 2024. Data pull from full year 2022 and full year 2023. All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. P1017370125
-
4 CVS Health Analytics, 2024. CVS Commercial clients. All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. P1017640325
-
5 CVS Health Analytics, 2023. Data pull from full year 2021 and full year 2022. All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. P1012410722
-
6 CVS Health Analytics, 2024. Weight Management Pilot Results. P1017690425
-
7 CVS Health Analytics, July 2024. Prior authorization data for book of business. P101753032
-
8 CVS Health Analytics, 2022. Data from 2021. Two approaches were employed to derive a rate card that can tie closure of care gaps to medical cost savings (MCS): (A) Estimated the value of closing a care gap statistically based on its observed impact on improving A1C and used values from medical literature to estimate how improvement in A1C translates to dollars of MCS; and (B) Used literature to estimate the value of closing care gaps that aren’t expected to directly drive improvements in A1C outcomes. Relative rates were then scaled such that the rate card times incremental gaps closed is equal to a conservative estimate of MCS for enrolled members. As part of its ongoing quality improvement activities, CVS Caremark conducted a retrospective assessment of program quality using established standards. Health outcome results, savings projections and performance ratings are based on CVS Caremark data. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. Client-specific modeling available upon request. P1012861022
-
9 Analysis estimates 30% average decrease in diabetes-specific drug spend based on before and after analysis of Virta program results. This estimate was corroborated by published Virta studies.
-
10 CVS Caremark Member Experience Survey, 2025. P1009480721
-
11 CVS Caremark Client Relationship Measurement Survey, 2023. P1013960223